Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

GSK Sets Time Of Tender Offer To Buy Human Genome Sciences To July 20

RELATED NEWS
Trade GSK now with 

GlaxoSmithKline Plx (GSK: Quote, GSK.L) Friday announced that it has set the time of its tender offer to acquire all of the outstanding shares of Human Genome Sciences (HGSI) at a price of $13.00 per share in cash till 5.00 p.m New York City time on July 20, 2012.

The company stated that the tender offer is due to expire after 16th July 2012, the deadline set by HGS for submission of definitive acquisition proposals in its strategic alternatives review process which began on 19 April after GSK made a private proposal on 11 April.

GSK stated that the time for the expiry of the tender offer till July 20 will provide HGS shareholders the opportunity to evaluate the outcome of the HGS Board's process relative to GSK's offer.

GSK's offer, which is not conditioned on due diligence or financing, represents a premium of 81 percent to HGS's closing share price of US$7.17 on 18 April, the last trading day before HGS publicly disclosed GSK's private offer.

Click here to receive FREE breaking news email alerts for GlaxoSmithKline PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Nike Inc., the world's largest athletic shoes and apparel maker, said Thursday after the markets closed that its second quarter profit rose 23% from last year, helped by higher revenue and improved gross margin. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. Citing extreme fluctuation of the ruble, Apple Inc. (AAPL) has reportedly discontinued its online sales of products in Russia. Despite efforts of the Russian central bank, the ruble has been spiraling downward, with oil prices plunging to historic levels. The ruble shed around 19 percent on Wednesday.... General Motors said it has halted the delivery of cars to dealerships in Russia as it strives to overcome the business risks stemming from the collapse of the ruble.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.